Nexalis Therapeutics Initiates Phase 2 Trial for IRX-211 in Breakthrough Cancer Pain
Key Insights
Nexalis Therapeutics (search) has screened the first patient in its Phase 2 trial for IRX-211, an investigational inhaled therapy for breakthrough cancer pain (search) treatment.
The multicentre, randomised, double-blind, placebo-controlled crossover trial will enrol approximately 156 adult cancer (search) patients experiencing breakthrough pain despite stable opioid therapy.
IRX-211 demonstrated excellent safety profile, rapid systemic exposure, and consistent pharmacokinetics in Phase 1 studies with healthy volunteers.
Nexalis Therapeutics (search) Ltd (ASX: NX1) has achieved a significant clinical milestone by screening the first patient in its Phase 2 trial for IRX-211, an investigational inhaled therapy for breakthrough cancer pain (search) (BTcP). This advancement marks the transition from preclinical development into controlled clinical evaluation within the intended patient population for this Australian clinical-stage drug development company.
Phase 2 Trial Design and Objectives
The Phase 2 study is structured as a multicentre, randomised, double-blind, placebo-controlled, crossover trial designed to assess the efficacy, safety, and patient-reported outcomes of IRX-211. The trial will enrol adult cancer (search) patients who experience breakthrough cancer pain (search) despite receiving stable background opioid therapy.
The study consists of two distinct phases: an open-label titration phase (Part A) to identify an individualised effective dose for each patient, followed by a double-blind crossover phase (Part B) for within-patient comparison against placebo. The trial aims to recruit approximately 156 patients, building on the foundation of a Phase 1 program conducted in healthy volunteers.
Preclinical Safety and Pharmacokinetic Profile
The Phase 1 program in healthy volunteers demonstrated an excellent safety profile for IRX-211, along with rapid systemic exposure and consistent pharmacokinetics. These results provided the scientific foundation for advancing the compound into patient studies and informed the design of the current Phase 2 trial.
Market Opportunity and Unmet Medical Need
Breakthrough cancer pain (search) represents a high-burden and often inadequately addressed condition within oncology supportive care. The global cancer (search) pain market is estimated to reach approximately US$11 billion by 2028, highlighting the substantial commercial opportunity for effective treatments in this therapeutic area.
IRX-211 is designed as a proprietary inhaled therapy, aiming to provide rapid, predictable, and patient-controlled relief that aligns with the critical needs of breakthrough cancer pain (search) patients. This approach addresses the limitations of current treatment options and the rapid onset characteristics of pain episodes.
Clinical Significance and Future Outlook
Nexalis Therapeutics (search) CEO Darryl Davies emphasized that screening the first patient signifies the beginning of generating efficacy data in patients, addressing a substantial treatment gap due to the limitations of current opioid options and the rapid onset of pain episodes. The company anticipates this study will establish a strong foundation for demonstrating clinical benefit and create potential future partnering opportunities.
The initiation of this Phase 2 trial represents a crucial advancement in Nexalis Therapeutics (search)' development program, transitioning from safety evaluation to efficacy assessment in the target patient population suffering from breakthrough cancer pain (search).